Abingdon Health Share Discussion Threads

[average down mug] 06/10/2021 11:58

Nice big buys coming in above 48

[bamboo2] 06/10/2021 11:47

Pwhite wants attention. Misinformation from him is best filtered. Iom

[average down mug] 06/10/2021 11:38

MMS holding this back with spread its going to be blue if not I’ll eat my cat’s dinner!! Lucky for me he likes salmon so it’s a win win situation 🤣👍👍

[average down mug] 06/10/2021 11:23

48.9 to buy now 🚀🚀🚀🚀8640;🚀Ԇ40;

[pwhite73] 06/10/2021 10:59

volsung - "Got a few more at 46.7p Probably mad"

You're not mad you just don't understand how the system works today. You can't believe prices are this low and you're convinced of a bounce back. It might happen but its no coincidence the price is now just under at what you bought at.

[average down mug] 06/10/2021 09:38

Going blue well done anyone who got in today enjoy the rise 😲☝A039;

[danessex] 06/10/2021 09:22

Start of good things rolling into winter

[volsung] 06/10/2021 09:18

Got a few more at 46.7p
Probably mad

[monte1] 06/10/2021 09:08

The above example you quote in relation to SCWorx cites ‘received an order….’. The Vatic press release confirms a strategic partnership including a manufacturing agreement with the potential to produce 70 -100m per year. Clearly that potential will only be fulfilled if demand exists and Vatic secure sales orders to that extent.
Rather a significant difference don’t you think?

Moreover, in your example it appears to say that trading was suspended after the veracity of the order was questioned by a short seller but the order was actually confirmed a few days later. Hmm.

[pwhite73] 06/10/2021 09:03

monte1 - "I am not aware that Abington/Vatic have made such claims unless you can confirm otherwise?"

Yes they have made such claims its in the Vatic news release below. 70 - 100 million per year. WTF



"This strategic partnership offers the potential for 70-100 million UK invented and manufactured covid tests per year."

[riddlerone] 06/10/2021 08:55

Thanks bamboo2 for Vatic's accurate financial position based on all the facts available not just selective.

[monte1] 06/10/2021 08:52

I am not aware that Abington/Vatic have made such claims unless you can confirm otherwise?

[pwhite73] 06/10/2021 08:47

The Abingdon/Vatic story is completely bogus. US regulators are much tougher against this kind of behaviour. At the start of the pandemic the SEC suspended several companies including SCworx for putting out questionable orders to boost the share price.



"The SEC has halted trading in SCWorx (WORX) in apparent response to concerns over its previously announced multimillion-test order for COVID-19 blood tests.
On April 13, the company announced that it received an order for 2M tests from virtual healthcare network Rethink My Healthcare with a provision for additional orders for 2M tests per week for 23 weeks, an order it confirmed on April 17 after short seller Hindenburg Research published a report questioning its veracity."

[dave4545] 06/10/2021 08:08

No Rns again is never good news with this one

48-50p

Cannot sell my small amount and offering 48.1p on that spread so it looks like it's heading towards 45-47p range early doors

[bamboo2] 05/10/2021 22:55

Rapid COVID-19 test provider raises £4.6m in seed round
16 JULY 2021 09:28


Vatic, a UK healthtech start-up....



They have also been funded by Innovate UK.

[bamboo2] 05/10/2021 21:01

If you are worried about the cash needed to start manufacturing, Vatic will be well aware of the situation the currently exists between ABDX and UK Govt.

Vatic are an extremely well funded Oxford based startup, and will be able to pay some cash up front, if that is what it takes to get the production line rolling. imo

[bamboo2] 05/10/2021 20:58

For the record, this is the Vatic press release...




October 4, 2021
Vatic announces manufacturing partnership with Abingdon Health
Abingdon Health plc (“Abingdon Health”), a leading international developer and manufacturer of high quality and effective rapid tests, and Vatic Health Limited (“Vatic”), a UK born health-tech company today announce that they have signed a manufacturing and supply agreement for the Vatic KnowNow™ rapid antigen test, used to detect active SARS CoV-2 in a saliva swab.

The innovative science of Vatic’s KnowNow Test combined with one of the largest manufacturers of lateral flow tests in Europe is a powerful and important partnership. providing a unique infectiousness test that is vital in the UK and globally.



Under the terms of the agreement, the test will be manufactured by Abingdon Health using its larger manufacturing capacity. This will provide Vatic with immediate access to high volume manufacturing and distribution, enabling the company to meet the expected demand for its antigen test in the UK and overseas.



This strategic partnership offers the potential for 70-100 million UK invented and manufactured covid tests per year. The test is registered in the UK and EU already, and a clinical trial is ethically approved and ready to begin in the US to seek emergency use authorisation there, with multiple other geographies in the export pipeline across Asia, Africa and South America.



Vatic has developed a new class of covid test that is the most specific on the market (99.9% Specificity). This gives it a very low rate of false positives - 0 in their clinical studies so far. This makes KnowNow the perfect tool for the new world where screening is key and the majority of test subjects will be negative. Where most people are negative, even a low incidence of false positives can create large-scale disruption as people are told to isolate when they aren’t actually infectious. KnowNow enables testing to keep people safe, whilst minimising disruption, increasing trust and keeping society and the economy open.



KnowNow Tests are also purposefully designed to be resistant to mutations, which are increasing exponentially in frequency over time, so it is future proofed to keep on working. As a final bonus, the test uses a saliva swab, which is more like brushing your teeth than sticking something up your nose or down your throat, music to the ears of many!




The KnowNow Test (www.knownow.com) is an easy-to-use saliva COVID-19 Spike Test which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies “infectious” or “active” copies of the virus which are capable of cell entry and thereby infect a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive after the end of the window during which they are infectious. Furthermore, the unique detection mechanism of the KnowNow Test has been purposefully designed from the ground up to be far more robust to mutation than traditional antigen tests, making it future proofed for ongoing COVID-19 testing.



KnowNow is the most specific COVID-19 assay that exists with zero false positives in studies (99.9% specificity, compared against 99.7% for Innova). The unique technology is CE Marked and MHRA registered for professional use across the UK and the EU and Vatic is currently working with retail, transport, manufacturing and hospitality companies to deploy its technology.





Chris Yates, Chief Executive Officer of Abingdon Health, commented: “We are delighted to be working with Vatic on the technology transfer of their cutting edge COVID-19 test into Abingdon Health and to have secured this long-term manufacturing arrangement. Having completed the first phase of the expansion of our manufacturing capacity, we are now at the forefront of COVID-19 rapid testing and part of the UK’s diagnostic manufacturing capacity. The agreement with Vatic is testament of our ability to provide high-quality services for our partners, whether for COVID-19 tests or non-COVID assays.”


Alex Sheppard, co-founder of Vatic, said: “We are now moving into a new phase where the pandemic as we knew it is over, and now we are having to deal with disruption as we learn to live with the virus. Unfortunately with the rise of several mutations across the world, vaccinations alone are not the total solution. Regular testing technologies are needed to help reduce the overall spread and keep the economy back up and running. Our unique test technology, combined with a UK-based manufacturing roll-out is a major milestone in testing. With the potential to manufacture two million tests per month initially, and significantly more beyond this as we scale, this deal will help us ensure the hard-fought wins around societal reopening are retained and we can really make a global impact. COVID-19 testing will remain alongside booster vaccinations, a key pillar of our collective biosecurity.”

[bamboo2] 05/10/2021 20:55

monte, jak seems to think if he says the same thing enough times it will become true.

He doesn't want to accept that the capex spending in H1 was a once off occurrence.

There's no point in arguing.

[monte1] 05/10/2021 15:15

Jak

Normally can’t disagree with your views on AIM trash but I am not sure that you are barking up the right tree here. The vast bulk of the cash burn during the period that you mention was non-recurring CAPEX utilised in upgrading and increasing capacity. The OPEX cash outflow is nothing like a cursory look at the first half may indicate - and it is being managed (witness the headcount reduction following the GLP refusal to pay). What is less clear is the extent that orders and resultant income are covering the OPEX. There is still a possibility that reserves are running thin and further funding required but that is not entirely clear as yet. imco this is a better gamble than much of the dross out there at the moment. I could be wrong but, as always, time will tell.